Sodium-glucose cotransporter - 2 (SGLT-2) inhibitors also delay progression of renal disease in selected patients with diabetic nephropathy (estimated glomerular filtration rate [eGRF] < 25 to 30 mL / minute and urine albumin / creatinine ratio > 300 mg / g).